Problem: IgG is transformed from maternal serum into the offspring as passive immunization by FcRn expressed in placenta and/or infant intestine. This study aimed to investigate the quantitative correlation between IgG and FcRn during gestation and lactating periods in rat.
Method Of Study: ELISA was performed to determine the variation of maternal and offspring IgG. Western blot and RT-qPCR were carried out to characterize FcRn expression in placenta and infant intestine.
Results: Maternal serum IgG appeared higher in first 2 weeks of lactation. The embryo IgG was in accordance with the FcRn expression in placenta. During the post-natal, the serum IgG concentration in feta was obviously lower than maternal IgG on day 0 before uptaking colostrums and rapidly increased on day 1.
Conclusion: These findings would provide clues for the endogenous transportation and exogenous administration of IgG for a better IgG intervention in offspring.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/aji.12465 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical efficacy of efgartigimod combined with intravenous methylprednisolone in the acute phase of neuromyelitis optica spectrum disorders.
Orphanet J Rare Dis
December 2024
Department of Neurology, The First Affiliated Hospital, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Sun Yat-Sen University, No. 58 Zhongshan Road 2, Guangzhou, 510080, China.
Background: Neuromyelitis Optica Spectrum Disorders (NMOSD) comprise a group of autoimmune-mediated, inflammatory, demyelinating central nervous system diseases caused by aquaporin-4 (AQP4) IgG autoantibodies. Efgartigimod is a human IgG Fc fragment that reduces antibody titers by targeting the neonatal Fc receptor (FcRn). This study documents the efficacy of efgartigimod combined with intravenous methylprednisolone (IVMP) in the acute phase of NMOSD.
View Article and Find Full Text PDFEvaluation of the effect of rozanolixizumab on pregnancy outcomes and pre- and postnatal development in cynomolgus monkeys.
Reprod Toxicol
December 2024
Labcorp, Münster, Germany.
Rozanolixizumab, a humanised immunoglobulin (Ig) G4 monoclonal antibody that selectively inhibits binding of IgG to the neonatal Fc receptor (FcRn), was evaluated in an embryo-foetal enhanced pre- and postnatal development (ePPND) study. Pregnant female cynomolgus monkeys (19 per group) received subcutaneous rozanolixizumab 50 mg/kg or 150 mg/kg or vehicle every 3 days from gestation day 20 until delivery. The proportion of pregnancy losses was 15.
View Article and Find Full Text PDFDiversity in Naturally Acquired Immunity to Group B Streptococcus: A Comparative Study of Women from Bangladesh, Malawi, and the United Kingdom.
J Infect Dis
December 2024
Department of Clinical Infection, Microbiology and Immunology, University of Liverpool, Liverpool, United Kingdom.
Background: Significant disparities in Group B Streptococcus (GBS) colonisation and neonatal disease rates have been documented across different geographical regions. For example, Bangladesh reports notably lower rates compared to the United Kingdom (UK) and Malawi. This study investigates whether this epidemiological variability correlates with the immune response to GBS in these regions.
View Article and Find Full Text PDFEnhanced Gut-to-Liver Oral Drug Delivery via Ligand-Modified Nanoparticles by Attenuating Protein Corona Adsorption.
ACS Nano
December 2024
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
The development of effective oral drug delivery systems for targeted gut-to-liver transport remains a significant challenge due to the multiple biological barriers including the harsh gastrointestinal tract (GIT) environment and the complex protein corona (PC) formation. In this study, we developed ligand-modified nanoparticles (NPs) that enable gut-to-liver drug delivery by crossing the GIT and attenuating PC formation. Specifically, mesoporous silica nanoparticles (MSNs) were functionalized with peptides targeting the neonatal Fc receptor (FcRn), capitalizing on FcRn expression in the small intestine and liver for targeted drug delivery.
View Article and Find Full Text PDFTargeting the neonatal Fc receptor (FcRn) is not beneficial in an animal model of chronic neuritis.
Immunol Res
December 2024
Department of Neurology, Center for Translational Neuro- and Behavioural Sciences, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
The inhibition of the neonatal Fc receptor (FcRn) is a promising therapeutic pathway in certain autoimmune disorders to reduce the amount of circulating pathogenic IgG autoantibodies by interfering with their recycling system. FcRn antibodies are currently being tested in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). This study aimed to investigate the therapeutic potential of an antibody targeting FcRn in the intracellular adhesion molecule 1 (ICAM1)-deficient NOD mouse-a model representative for many aspects of human CIDP.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!